37 RESULTS
COMMENT The report on CCR5 provides prima facie evidence of the long-held notion that much of the damage to neurons in brain disease occurs not as a result of the primary event, but due to activation of signaling by cytokines and other transmitters. This ...
COMMENT In 1990, a series of independent papers converged to implicate a role for protein kinase C (PKC) in AD. Eliezer Masliah and Greg Cole, working in Tsunao Saitoh’s lab, discovered deficiencies in PKC activity in AD brain and fibroblasts (Masliah et al., ...
COMMENT The Mez et al. report is important in pointing toward the possible roles of youth, high school, and collegiate sports in the pathogenesis of CTE. Also on CTE, we just reported the first image of T807 retention in a retired NFL player. It shows a ...
COMMENT My reaction is that the new pro-retromer drug is brilliant and essential, and at the very least, we have a terrific new tool for cell biology at the bench. In contemplating its use in treating or preventing AD, there are some caveats that tend to keep me ...
COMMENT I think that there a lot of uncontrolled and unknowable variables at work here. The post traumatic brain injury (TBI) amyloidosis probably peaks very early and then might be resolved completely. I assume that the propensities for depositing and the speed ...
COMMENT For five decades, chronic traumatic encephalopathy (CTE), formerly known as dementia pugilistica, was exclusively associated with delayed neurodegeneration with prominent tauopathy. The clinical syndromes varied from pure dementia to parkinsonism without ...
COMMENT The data jibe well with longstanding human and mouse data showing that APOE4 enhances brain amyloid pathology robustly (especially cerebral amyloid angiopathy). It is heartening to think that after 20 years of APOE4 linkage to AD, there are new exciting ...
COMMENT CMS declined coverage recommendation because there is no evidence that amyloid PET scan results have any impact on outcome. We might need a new strategy for Amyvid® coverage. We may not be able to show that intervening therapeutically at the age covered ...
COMMENT There has been a longstanding curiosity in the field of Alzheimer's research regarding possible relationships between APP/Aβ and the process of apoptosis. Aβ oligomer toxicity is closely associated with neurotoxicity, but typical programmed cell ...
COMMENT One of the most vexing issues in elucidating the molecular pathogenesis of AD has been the challenge of working out whether there exist neurotoxic pathways that act independently of the genesis of amyloid-β oligomers. Such pathways have been identified ...
COMMENT The question is unresolved as to whether repetitive mild traumatic brain injury (TBI) causes little bursts of Aβ that initiate and propagate tauopathy in young hosts, but then the Aβ is cleared away by the time they die. The conundrum is that 1) if you ...
COMMENT The cholesterol/ApoE/Aβ connection is one of the most challenging areas in AD research. Studies of statins led to very dramatic benefits in mice that, so far, have not been translatable to humans. Elucidation of statins' effects led many labs, ...
COMMENT To answer the rhetorical question presented by Sperling et al., "Why do we keep testing drugs aimed at the initial stages of the disease process in patients at the endstage of the illness?", it is because prevention trials are almost too ...
COMMENT This work looks very solid and very interesting. We seem to have moved from the “secretase generation” to the “sortase generation,” what with LRP, vps35, SORL1, and SORCS1 all playing key roles in sorting APP and its C-terminal fragments in and out of Aβ ...
COMMENT The data here are beautiful and compelling, especially the demonstration of the temporal relationship between the accumulation of oligomers and the changes in interstitial fluid (ISF) lactate. Once again, the chicken-and-egg test shows that ...
